The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas

Journal of Neuropathology and Experimental Neurology

Volumn 75, Issue 1, 2016, Pages 4-18

  Tanboon, Jantima ^a,b   Williams, Erik A ^a   Louis, David N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Astrocytoma; Glioblastoma; Glioma; Immunohistochemistry; Molecular markers; Neuropathology; Oligodendroglioma

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FAR UPSTREAM ELEMENT BINDING PROTEIN 1; HISTONE H3; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NUCLEAR PROTEIN; NUCLEAR PROTEIN ATRX; PROTEIN P53; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TUMOR MARKER;

CANCER DIAGNOSIS; DNA SEQUENCE; GENE MUTATION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETICS; MUTATION;

ANIMALS; BIOMARKERS, TUMOR; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84961855495     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1093/jnen/nlv009     Document Type: Review

References (137)

1. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: A new horizon. Lancet Oncol 2013;14:e370-9
2. Appin CL, Brat DJ. Molecular genetics of gliomas. Cancer J 2014; 20:66-72
3. Biegel JA, Rorke LB, Emanuel BS. Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain. N Engl J Med 1989;321:906
4. Judkins AR, Mauger J, Ht A, et al. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 2004;28:644-50
5. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12
6. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599-601
7. Camelo-Piragua S, Jansen M, Ganguly A, et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocy-tosis. Acta Neuropathol 2010;119:509-11
8. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone de-methylation and results in a block to cell differentiation. Nature 2012;483:474-8
9. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013;3:730-41
10. Oizel K, Gratas C, Nadaradjane A, et al. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. Cell Death Dis 2015;6:e1704
11. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1, 010 diffuse gliomas. Acta Neuropathol 2009;118:469-74
12. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendrog-lial gliomas. Brain Tumor Pathol 2011;28:177-83
13. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481-98
14. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
15. Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 2013;125:621-36
16. Horbinski C, Kofler J, Kelly LM, et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009;68:1319-25
17. Camelo-Piragua S, Jansen M, Ganguly A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: Chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 2011;70:110-5
18. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560-6
19. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483: 479-83
20. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709-22
21. Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol 2013;15:469-79
22. Sabha N, Knobbe CB, Maganti M, et al. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol 2014;16:914-23
23. Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocyto-mas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014;16:81-91
24. Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014;128: 561-71
25. Brat DJ, Cagle PT, Dillon DA, et al. Template for reporting results of biomarker testing of specimens from patients with tumors of the central nervous system. Arch Pathol Lab Med 2015;139:1087-93
26. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immu-nohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129:133-46
27. Huse JT, Nafa K, Shukla N, et al. High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocy-tomas. Acta Neuropathol 2011;122:367-9
28. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of glio-mas. Acta Neuropathol 2010;120:707-18
29. Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and ana-plastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 2015;129:867-73
30. Horbinski C, Kofler J, Yeaney G, et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 2011;21:564-74
31. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013;81:1515-22
32. van den Bent MJ, Hartmann C, Preusser M, et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol 2013;112:173-8
33. Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 2015;130:407-17
34. Preusser M, Wohrer A, Stary S, et al. Value and limitations of immuno-histochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 2011;70:715-23
35. Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol 2013;15:718-26
36. Jabbar KJ, Luthra R, Patel KP, et al. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol 2015;39:454-61
37. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245-54
38. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009;137:413-31
39. Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: A lifeguard with a licence to kill. Nat Rev Mol Cell Biol 2015;16:393-405
40. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21
41. Takami H, Yoshida A, Fukushima S, et al. Revisiting TP53 mutations and immunohistochemistry-A comparative study in 157 diffuse gliomas. Brain Pathol 2015;25:256-65
42. Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov 2014;13:217-36
43. Riley T, Sontag E, Chen P, et al. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12
44. Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, et al. p53 in nonneo-plastic central nervous system lesions: An immunohistochemical and genetic sequencing study. Neurosurgery 2002;51:1246-54; discussion 54-5
45. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89
46. Gillet E, Alentorn A, Doukoure B, et al. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol 2014;118:131-9
47. Clynes D, Higgs DR, Gibbons RJ. The chromatin remodeller ATRX: A repeat offender in human disease. Trends Biochem Sci 2013;38: 461-6
48. Levy MA, Kernohan KD, Jiang Y, et al. ATRX promotes gene expression by facilitating transcriptional elongation through guanine-rich coding regions. Hum Mol Genet 2015;24:1824-35
49. Clynes D, Gibbons RJ. ATRX and the replication of structured DNA. Curr Opin Genet Dev 2013;23:289-94
50. Clynes D, Jelinska C, Xella B, et al. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun 2015;6:7538
51. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012;124:615-25
52. Berghoff AS, Stefanits H, Heinzl H, et al. Clinical neuropathology practice news 4-2012: levels of evidence for brain tumor biomarkers. Clin Neuropathol 2012;31:206-9
53. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011;333:425
54. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013;126:443-51
55. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014;46:444-50
56. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012;124:439-47
57. Cai J, Yang P, Zhang C, et al. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: Evidence from the whole tran-scriptome sequencing of 169 samples samples. Oncotarget 2014; 5:2551-61
58. Mangerel J, Price A, Castelo-Branco P, et al. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol 2014;128:853-62
59. Nguyen DN, Heaphy CM, de Wilde RF, et al. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 2013;23:237-43
60. Abedalthagafi M, Phillips JJ, Kim GE, et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: A multi-institutional study of 214 astrocytomas. Mod Pathol 2013;26:1425-32
61. Flynn RL, Cox KE, Jeitany M, et al. Alternative lengthening of telo-meres renders cancer cells hypersensitive to ATR inhibitors. Science 2015;347:273-7
62. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-203
63. Gielen GH, Gessi M, Buttarelli FR, et al. Genetic analysis of diffuse high-grade astrocytomas in infancy defines a novel molecular entity. Brain Pathol 2015;25:409-17
64. Biterge B, Schneider R. Histone variants: Key players of chromatin. Cell Tissue Res 2014;356:457-66
65. Szenker E, Ray-Gallet D, Almouzni G. The double face of the histone variant H3.3. Cell Res 2011;21:421-34
66. Elsasser SJ, Noh KM, Diaz N, et al. Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. Nature 2015;522:240-4
67. Ezponda T, Licht JD. Molecular pathways: Deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clin Cancer Res 2014;20:5001-8
68. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013;340:857-61
69. Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014; 46:451-6
70. Louis DN, Perry A, Burger P, et al. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014;24:429-35
71. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2015 (in press)
72. Korshunov A, Ryzhova M, Hovestadt V, et al. Integrated analysis of pe-diatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015; 129:669-78
73. Gielen GH, Gessi M, Hammes J, et al. H3F3A K27M mutation in pedi-atric CNS tumors: A marker for diffuse high-grade astrocytomas. Am J Clin Pathol 2013;139:345-9
74. Hochart A, Escande F, Rocourt N, et al. Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. Ann Clin Transl Neurol 2015;2:439-43
75. Feng J, Hao S, Pan C, et al. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol 2015 Jul 15. pii:S0046-8177(15)00244-0
76. Bechet D, Gielen GG, Korshunov A, et al. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 2014;128: 733-41
77. Venneti S, Santi M, Felicella MM, et al. A sensitive and specific histo-pathologic prognostic marker for H3F3A K27M mutant pediatric glio-blastomas. Acta Neuropathol 2014;128:743-53
78. Horbinski C. To BRAF or not to BRAF: Is that even a question anymore? J Neuropathol Exp Neurol 2013;72:2-7
79. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9
80. Das Thakur M, Stuart DD. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors. Clin Cancer Res 2014;20:1074-80
81. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011;10: 385-94
82. Berghoff AS, Preusser M. BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. Curr Opin Neurol 2014;27: 689-96
83. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405
84. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013;45: 602-12
85. Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 2015;33:1015-22
86. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013;37:685-98
87. Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol 2015;39:528-40
88. Chappe C, Padovani L, Scavarda D, et al. Dysembryoplastic neuroepi-thelial tumors share with pleomorphic xanthoastrocytomas and ganglio-gliomas BRAF(V600E) mutation and expression. Brain Pathol 2013; 23:574-83
89. Koelsche C, Sahm F, Paulus W, et al. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathol Appl Neurobiol 2014;40:337-44
90. Chi AS, Batchelor TT, Yang D, et al. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013;31:e233-6
91. Gupta K, Orisme W, Harreld JH, et al. Posterior fossa and spinal gan-gliogliomas form two distinct clinicopathologic and molecular subgroups. Acta Neuropathol Commun 2014;2:18
92. Dahiya S, Haydon DH, Alvarado D, et al. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013;125:901-10
93. Prabowo AS, Iyer AM, Veersema TJ, et al. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol 2014;24:52-66
94. Ihle MA, Fassunke J, Konig K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immuno-histochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 2014;14:13
95. Koelsche C, Wohrer A, Jeibmann A, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013;125:891-900
96. Mordes DA, Lynch K, Campbell S, et al. VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations. Am J Clin Pathol 2014;141:811-5
97. Maire CL, Ligon KL. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol 2014;16 Suppl 8:viii1-6
98. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-72
99. Jutten B, Rouschop KM. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle 2014;13:42-51
100. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30
101. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glio-blastoma. Am J Pathol 2007;170:1445-53
102. Zadeh G, Bhat KP, Aldape K. EGFR and EGFRvIII in glioblastoma: Partners in crime. Cancer Cell 2013;24:403-4
103. Fan QW, Cheng CK, Gustafson WC, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblas-toma. Cancer Cell 2013;24:438-49
104. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77
105. Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro Oncol 2014;16(Suppl 8):viii7-13
106. Cominelli M, Grisanti S, Mazzoleni S, et al. EGFR amplified and over-expressing glioblastomas and association with better response to adjuvant metronomic temozolomide. J Natl Cancer Inst 2015;107:pii
107. Weller M, Kaulich K, Hentschel B, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolo-mide radiochemotherapy. Int J Cancer 2014;134:2437-47
108. Horbinski C, Hobbs J, Cieply K, et al. EGFR expression stratifies oligo-dendroglioma behavior. Am J Pathol 2011;179:1638-44
109. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63:700-7
110. Fan CH, Liu WL, Cao H, et al. O6-methylguanine DNA methyltransfer-ase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis 2013;4:e876
111. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003
112. Wick W, Weller M, van den Bent M, et al. MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014;10:372-85
113. Aldape K, Zadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129:829-48
114. Weller M, Tabatabai G, Kastner B, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: The DIRECTOR Trial. Clin Cancer Res 2015;21:2057-64
115. Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: An analysis of the NOA-08 study collective. Neuro Oncol 2013;15:1017-26
116. Mason S, McDonald K. MGMT testing for glioma in clinical laboratories: Discordance with methylation analyses prevents the implementation of routine immunohistochemistry. J Cancer Res Clin Oncol 2012;138:1789-97
117. Preusser M, Charles Janzer R, Felsberg J, et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: Observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008;18: 520-32
118. Jimenez G, Shvartsman SY, Paroush Z. The Capicua repressor-a general sensor of RTK signaling in development and disease. J Cell Sci 2012;125:1383-91
119. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011;333:1453-5
120. Chittaranjan S, Chan S, Yang C, et al. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget 2014;5:7960-79
121. Chan AK, Pang JC, Chung NY, et al. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligoden-droglial tumors. Mod Pathol 2014;27:332-42
122. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012;226:7-16
123. Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligo-dendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012;123:853-60
124. Nagaishi M, Suzuki A, Nobusawa S, et al. a-Internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion. Brain Tumor Pathol 2014;31:257-64
125. Zhang J, Chen QM. Far upstream element binding protein 1: A commander of transcription, translation and beyond. Oncogene 2013;32: 2907-16
126. Jang M, Park BC, Kang S, et al. Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene 2009;28:1529-36
127. Jacob AG, Singh RK, Mohammad F, et al. The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA. J Biol Chem 2014;289:17350-64
128. Li H, Wang Z, Zhou X, et al. Far upstream element-binding protein 1 and RNA secondary structure both mediate second-step splicing repression. Proc Natl Acad Sci USA 2013;110:E2687-95
129. Ding Z, Liu X, Liu Y, et al. Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with c-Myc and cell proliferation. Mol Carcinog 2015;54:405-15
130. Baumgarten P, Harter PN, Tonjes M, et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligoden-droglial differentiation, IDH1 mutation and 1p/19q loss of heterozygos-ity. Neuropathol Appl Neurobiol 2014;40:205-16
131. Hill R, Cautain B, de Pedro N, et al. Targeting nucleocytoplasmic transport in cancer therapy. Oncotarget 2014;5:11-28
132. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integra-tive sequencing. Nat Genet 2013;45:180-5
133. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 2013;45:131-2
134. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericy-toma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 2013;125:651-8
135. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012;12:818-34
136. Kaur K, Kakkar A, Kumar A, et al. Integrating molecular subclassifica-tion of medulloblastomas into routine clinical practice: A simplified approach. Brain Pathol 2015 [Epub ahead of print]
137. Kahlert UD, Suwala AK, Koch K, et al. Pharmacologic Wnt inhibition reduces proliferation, survival, and clonogenicity of glioblastoma cells. J Neuropathol Exp Neurol 2015;74:889-900